Clinical Trial

Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 7, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will evaluate the safety and efficacy of NK520 in the treatment of relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.
Trial Details
NCT Number NCT06541444
Lead Sponsor Base Therapeutics (Shanghai) Co., Ltd.
Collaborators: Shanghai Pudong Hospital
Conditions Relapsed/Refractory Acute Myeloid Leukemia
Enrollment 9 participants
Start Date 2024-07-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-07